This raises the possibility that NUCB2 may be a prognostic parameter for PCa that is as or more reliable than the clinicopathologic factors currently in use and suggests the possibility to use NUCB2 in individualization of both patient prognosis and therapy. This evidence concerns the gene NUCB2 and posterior cortical atrophy.